A novel drug delivery system that allows hospital patients to
self-administer pain relief medication without an intravenous line
could be available in the US within six months, pending final Food
and Drug Administration (FDA) approval.
The launch of newer technology products with a wide range of
applications and the facility to deliver proteins, peptides, and
large molecules is expected to rake in market revenues, according
to a new report from market analysts Frost...